Phase 1/2 Open-label Dose Evaluation Study of AXO-Lenti-PD Gene Therapy for Parkinson’s Disease: Efficacy, Safety, and Tolerability Data from the Second Cohort at 6 Months
Objective: Results from cohort 2 in the Phase 1/2 SUNRISE-PD study (NCT03720418) at 6 months (6M) post administration of AXO-Lenti-PD (ALPD) gene therapy are presented.…Overcoming clinical research challenges during a pandemic: selection and implementation of digital phenotyping solutions in a natural history study of G2019S LRRK2 Parkinson’s disease.
Objective: To identify candidate wearable devices or digital solutions suitable for conducting the Timed Up and Go (TUG) test and evaluate real-world performance remotely during…PHYSICAL ACTIVITY AT HOME IS ABLE TO REDUCE THE WORSENING IN QUALITY OF LIFE IN PARKINSON’S DISEASE DURING COVID-19 PANDEMIC
Objective: To compare the effects of physical activity (PA) at home with and without remote supervision on the motor and non-motor aspects of daily life…The PD-1102 trial in advanced Parkinson’s disease: safety and clinical outcomes from a 3-year phase 1b study of AADC gene therapy administered via a posterior approach
Objective: To present 3-year safety and clinical outcome data from a phase 1b, open-label trial of VY-AADC01 (NBIb-1817) for Parkinson’s disease (PD) patients with motor…Weeding Through the Haze: A Survey on Cannabis Use Among People with Parkinson’s Disease
Objective: To identify themes in cannabis use among people with Parkinson’s disease to inform medical recommendations and the design of future clinical trials. Background: Parkinson’s…Pridopidine for the Treatment of Early Huntington’s Disease
Objective: Assess the efficacy of pridopidine 45 mg bid for maintenance of total functional capacity (TFC) and motor function in early HD patients. Background: Pridopidine…Translatable biomarkers in gene therapy for Huntington’s Disease: learnings from pre-clinical studies
Objective: We have developed AAV5-miHTT, a recombinant AAV-based gene therapy expressing an engineered microRNA that specifically binds to HTT exon1, resulting in lowering of both…Effect of herbal medicine against Parkinson’s Diseases- An in silico studies
Objective: To evaluate the effect of the bioactive compounds of Gymnema sylvestre on treatment of Parkinson’s diseases. Background: Neurodegenerative diseases, such as Parkinson’s and Alzheimer’s,…Gut Microbiota in Parkinson’s disease: influences of device-assisted therapies
Objective: To determine the temporal stability of gut microbiota (GM) profiles around the acute establishment of advanced Parkinson's disease (PD) therapies and describe resulting alterations in…Pridopidine for the treatment of Levodopa-induced Dyskinesia in patients with Parkinson’s disease
Objective: To assess the efficacy and safety of pridopidine in PD patients with Levodopa-induced dyskinesia (LID). Background: Pridopidine is a small molecule in clinical development…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 11
- Next Page »